Afya Limited reports financial, regulatory and capital-allocation developments for a Brazil-based medical education group and medical practice solutions provider. The company serves medical students and physicians through an end-to-end ecosystem that includes undergraduate medical education, residency preparation, continuing medical education, graduate programs and practice-management solutions.
Recurring company developments include IFRS financial results in Brazilian reais, medical-seat authorizations from Brazil’s Ministry of Education, campus-level capacity changes, credit-rating actions, dividends, share repurchases and board changes. Afya also reports activity in continuing education, B2B revenue, clinical management tools and the broader physician base that uses its education and medical practice platforms.
Afya (AFYA) signed a binding merger agreement with Yduqs on September 23, 2026, under which Yduqs would survive.
The exchange ratio is 6.408347 new Yduqs shares for each Afya share, subject to limited arithmetic adjustments. It allocates 69.0% of the combined company to Afya shareholders and 31.0% to existing Yduqs shareholders on a fully diluted basis; Bertelsmann would hold 47.4%. Afya’s Class A shares would be delisted from Nasdaq, and the combined company’s common shares would remain listed only on B3. Ineligible Afya shareholders would not receive combined-company shares; they are expected instead to receive net proceeds from a post-closing sale.
Completion requires both companies’ shareholder approvals, Brazilian antitrust approval, certain third-party consents and other conditions. The agreement calls for completion no later than March 31, 2028, subject to its extension provisions.
Afya Limited (AFYA) received authorization from Brazil’s Ministry of Education to add 17 medical seats at AFYA Cruzeiro do Sul in Cruzeiro do Sul, Acre. This raises the campus capacity to 67 medical seats. With this increase, Afya now has a total of 3,785 approved medical seats across its network, which the company describes as reinforcing its commitment to expanding quality medical education in Brazil.
Afya (Nasdaq: AFYA) confirmed that it is in early-stage discussions with Yduqs Participações (B3: YDUQ3) about a potential business combination, following Yduqs’ material fact disclosure. No binding agreement or obligation has been entered into by either company, and Afya cautions there is no assurance any transaction will occur.
Afya (Nasdaq: AFYA; B3: A2FY34) reported 2Q26 revenue of R$972.1 million, up 5.7% year over year, and 1H26 revenue of R$1,984.8 million, up 7.0%. Adjusted EBITDA reached R$406.5 million in 2Q26 and R$918.0 million in 1H26, rising 1.4% and 2.8% respectively, while margins declined 180–190 bps versus 2025.
Net income grew 14.0% in 2Q26 to R$201.3 million and 6.8% in 1H26 to R$463.1 million. Operating cash flow totaled R$805.5 million in 1H26, with cash of R$1,006.5 million. Afya returned R$447.9 million to shareholders (R$314.9 million in dividends and R$133.0 million in buybacks, about 3% of shares), equal to 105.8% of 1H26 free cash flow to equity. Moody’s reaffirmed Afya’s AAA.br rating with a stable outlook, and the company maintained 2026 guidance for revenue of R$3.95–4.10 billion and adjusted EBITDA of R$1.70–1.80 billion.
Afya (Nasdaq: AFYA; B3: A2FY34) announced the appointment of Marcelo Ken Suhara as Chair Member of its Audit, Risks and Ethics Committee, effective July 27, 2026. Suhara remains an independent Board member and Audit Committee financial expert, succeeding the late João Paulo Seibel de Faria.
Afya highlighted Faria’s contributions and offered condolences to his family. The Board of Directors includes two co-chairmen representing Bertelsmann SE & Co. KGaA and the Esteves family, additional members from both groups, and three independent directors, reflecting a mix of skills and experience.
Afya (Nasdaq: AFYA) held its Annual General Meeting on June 22, 2026, in Belo Horizonte, Brazil.
Shareholders approved and ratified Afya’s financial statements as of and for the fiscal year ended December 31, 2025, as set out in the Notice of Meeting dated June 2, 2026.
Afya (Nasdaq: AFYA; B3: A2FY34) released its 2025 Integrated Report, which it describes as reflecting its best operational performance since IPO. The report marks full adoption of the Integrated Reporting framework and offers an integrated view of performance, strategy and value creation.
The 2025 edition adds a chapter on technology and AI, explaining how Afya uses artificial intelligence in medical education and healthcare solutions through dedicated governance and selected applications. It also covers Afya’s academic model, ESG performance and risk management, including a second year above targets in its sustainability-linked loan with the IFC and integration of climate risks into its ERM model.
Afya (Nasdaq:AFYA) will hold its Annual General Meeting on June 22, 2026 at 10:00 a.m. BRT in Belo Horizonte, Brazil, with virtual access via webcast. Shareholders will vote on approving and ratifying the Company’s financial statements and auditor’s report for the year ended December 31, 2025.
Afya (Nasdaq: AFYA) reported 1Q26 results: revenue R$1,012.7M (+8.2% YoY), Adjusted EBITDA R$511.4M (+4.0% YoY) and Adjusted EBITDA margin 50.5% (‑200 bps YoY). Net income was R$261.8M and basic EPS was R$2.88 (+3.0%). Free cash flow was R$376.0M and cash was R$1,332.9M. Ecosystem reached ~303.6k users and approved medical seats totaled 3,768. Moody’s reaffirmed AAA.br with stable outlook. 2026 guidance: Revenue R$3,950–4,100M; Adjusted EBITDA R$1,700–1,800M; CAPEX R$340–380M.
Afya (Nasdaq: AFYA) announced that Moody's reaffirmed its AAA.br credit rating on May 6, 2026, with a stable outlook. The rating reflects revenue growth, above-industry margins, very strong credit metrics, exceptional cash generation, robust liquidity, a strong competitive position, and prudent financial policy.
Afya highlighted proactive liability management, disciplined capital allocation and an appetite for M&A as part of its credit profile.